Bms-813160

Other Medications

EU Not submitted to EMA ES Not available 1 Clinical Trials

Description

BMS-813160 is under investigation for its potential use in colorectal cancer (CRC), particularly as a targeted therapy to inhibit tumor growth and proliferation; however, it has not yet been approved by the FDA or widely used clinically for CRC treatment. Its efficacy and safety are currently being evaluated in clinical trials.

Mechanism of Action

BMS-813160 is an investigational small molecule that selectively inhibits the PI3K-delta and PI3K-gamma isoforms, which are involved in immune cell signaling pathways; it aims to modulate inflammation and immune responses.

Side Effects

Fatigue; nausea; diarrhea; neutropenia; thrombocytopenia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03184870 Phase 1
Archived
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
United States, Australia, Belgium, Canada, Germany, Spain

Quick Info

CategoryOther Medications
EU EMA StatusNot submitted to EMA
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.